Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Immuneering stock

Learn how to easily invest in Immuneering stock.

Immuneering is a biotechnology business based in the US. Immuneering shares (IMRX) are listed on the NASDAQ and all prices are listed in US Dollars. Immuneering employs 74 staff and has a trailing 12-month revenue of around $506,088.

How to buy Immuneering stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – IMRX. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Immuneering stock price (NASDAQ: IMRX)

Use our graph to track the performance of IMRX stocks over time.

Immuneering shares at a glance

Information last updated 2023-01-26.
Latest market close$4.17
52-week range$3.74 - $16.17
50-day moving average $5.21
200-day moving average $7.14
Wall St. target price$17.40
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.12

Buy Immuneering stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Immuneering stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immuneering price performance over time

Historical closes compared with the close of $4.17 from 2023-02-01

1 week (2023-01-26) -5.44%
1 month (2022-12-30) -14.02%
3 months (2022-11-02) -68.24%
6 months (2022-08-02) -30.27%
1 year (2022-02-02) -57.23%
2 years (2021-01-29) N/A
3 years (2020-01-29) N/A
5 years (2018-01-29) N/A

Immuneering financials

Revenue TTM $506,088
Gross profit TTM $926,888
Return on assets TTM -20.52%
Return on equity TTM -34.3%
Profit margin 0%
Book value $4.62
Market capitalisation $116.4 million

TTM: trailing 12 months

Immuneering share dividends

We're not expecting Immuneering to pay a dividend over the next 12 months.

Immuneering overview

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited. .

Frequently asked questions

What percentage of Immuneering is owned by insiders or institutions?
Currently 30.559% of Immuneering shares are held by insiders and 45.93% by institutions.
How many people work for Immuneering?
Latest data suggests 74 work at Immuneering.
When does the fiscal year end for Immuneering?
Immuneering's fiscal year ends in December.
Where is Immuneering based?
Immuneering's address is: 245 Main Street, Cambridge, MA, United States, 02142
What is Immuneering's ISIN number?
Immuneering's international securities identification number is: US45254E1073

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site